Meet the Novel Players in Hypertensive Kidney Disease: Septin4 and SIRT2.
Meet the Novel Players in Hypertensive Kidney Disease: Septin4 and SIRT2.
复制标题
DOI：
10.1161/circresaha.123.322552
复制
发表时间：
2023-03
影响因子：
20.1
通讯作者：
S. Dikalov;Annet Kirabo
中科院分区：
文献类型：
--
作者：
S. Dikalov;Annet Kirabo
尽管最近在治疗高血压方面取得了进展，但它仍然是一个巨大的负担。几乎一半的成年人患有高血压，全球估计有14亿人患有高血压，但只有四分之一的患者血压得到控制。这种疾病是中风、心肌梗死、心力衰竭和肾脏疾病的主要危险因素。在美国，近五分之一的高血压患者患有肾脏疾病，高血压是导致肾衰竭的第二大原因。2迫切需要新的治疗方法，以减少高血压肾病。了解其特定的分子病理机制有助于开发治疗这种毁灭性疾病的新疗法。
Despite recent advances in the treatment of hyper-tension, it remains a great burden. Almost one-half of the adults have hypertension, and an estimated 1.4 billion people have hypertension worldwide but only 1 in 4 patients have their blood pressure under control. 1 This disease represents a major risk factor for stroke, myocardial infarction, heart failure, and kidney disease. Nearly 1 in 5 people with high blood pressure have kidney disease, and hypertension is the second leading cause of kidney failure in the United States. 2 There is an urgent need for new therapies, which can reduce hypertensive kidney disease. Understanding the specific molecular pathological mechanisms can help to develop new therapies for treatment of this devastating disease.